While the monovalent high affinity anti-LYPD1 TCB, VHP354 showed tumor regressions down to 0.3 mg/kg, the in vivo potency of the bivalent low affinity anti-LYPD1 TCB, QZC131 showed tumor growth inhibition at 10-fold higher doses of 3 mg/kg. This evidence concerns the gene LYPD1 and neoplasm.